Literature DB >> 10435226

Medical management of benign prostatic hyperplasia.

A Chacon1, M Monga.   

Abstract

The management of benign prostatic hyperplasia has undergone a rapid evolution over the past decade from a surgical emphasis to a medical emphasis. Great strides in the development of alpha-adrenergic blockers, 5 alpha-reductase inhibitors and a variety of phytotherapeutics have fueled this evolution. This article reviews the past, present and future of the medical management of benign prostatic hyperplasia.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10435226     DOI： 10.1023/a:1008308819463

Source DB:  PubMed          Journal:  Geriatr Nephrol Urol        ISSN： 0924-8455


  5 in total

Review 1.  Update on the medical management of benign prostatic hyperplasia.

Authors:  Manoj Monga
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

2.  A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia.

Authors:  Fatih Hizli; M Cemil Uygur
Journal:  Int Urol Nephrol       Date:  2007-01-04       Impact factor: 2.370

Review 3.  Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).

Authors:  Wenqing Gao; James T Dalton
Journal:  Drug Discov Today       Date:  2007-02-07       Impact factor: 7.851

4.  Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.

Authors:  Wenqing Gao; Jeffrey D Kearbey; Vipin A Nair; Kiwon Chung; A F Parlow; Duane D Miller; James T Dalton
Journal:  Endocrinology       Date:  2004-08-12       Impact factor: 4.736

Review 5.  Role of anabolic agents in colorectal carcinogenesis: Myths and realities (Review).

Authors:  Theodore Krasanakis; Taxiarchis Konstantinos Nikolouzakis; Markos Sgantzos; Theodore Mariolis-Sapsakos; John Souglakos; Demetrios A Spandidos; Christina Tsitsimpikou; Aristidis Tsatsakis; John Tsiaoussis
Journal:  Oncol Rep       Date:  2019-10-03       Impact factor: 3.906
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.